# MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

> **NCT07000292** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Lupus Nephritis (LN)
- ANCA-Associated Glomerulonephritis

## Interventions

- **DRUG:** Injection of MSC303

## Key facts

- **NCT ID:** NCT07000292
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-05-20
- **Final completion:** 2027-02-20
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000292, "MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07000292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*